Repurposed drug has promising efficacy in shrinking NSCLC tumors

FDA will speed up public release of Complete Response Letters

FDA is shortening its timeline for publicizing Complete Response Letters, pledging to make them available to the public “promptly” after sponsors receive notice.

UC San Diego awarded $80M to expand clinical trials and train future researchers

UC San Diego and a growing coalition of regional institutions are making clinical research more accessible and more impactful across Southern California.

September 05, 2025

Vol.51 No.32

Clinical Roundup

IO Biotech’s vaccine misses on mPFS in phase III advanced melanoma trial

Cylembio (imsapepimut and etimupepimut, adjuvanted), an off-the-shelf therapeutic cancer vaccine, plus pembrolizumab narrowly missed on its primary endpoint of progression free survival for patients with unresectable or metastatic melanoma, according to phase III trial results.

September 05, 2025

Vol.51 No.32

Guest Editorial

Andrea Werblin Reid’s unflinching poetry documents the realities of cancer care, clinical trials, and loss
Her collection, “To See Yourself As You Vanish,” will be published three years after her death

I always liked poetry, but I was never a poet. I had to marry into that.

In phase III trial, epcoritamab regimen improves PFS in R/R follicular lymphoma

EPCORE FL-1 phase III trial results show that subcutaneous epcoritamab in combination with rituximab and lenalidomide reduced the risk of disease progression or death by 79% for patients with relapsed/refractory follicular lymphoma.

August 08, 2025

Vol.51 No.31

Clinical Conversation with The Cancer Letter

Will MCD tests revolutionize cancer screening? NCI begins enrollment in Vanguard “feasibility” trial to start finding out

The first large cancer screening/early detection initiative to be launched in 2025—the NCI-funded Vanguard study of multi-cancer detection tests—has started accruing patients through nine sites across the U.S.

July 25, 2025

Vol.51 No.29

By Sara Willa Ernst, Jacquelyn Cobb and Paul Goldberg

Repurposed drug has promising efficacy in shrinking NSCLC tumors

YOU MAY BE INTERESTED IN

FDA will speed up public release of Complete Response Letters

UC San Diego awarded $80M to expand clinical trials and train future researchers

IO Biotech’s vaccine misses on mPFS in phase III advanced melanoma trial

Andrea Werblin Reid’s unflinching poetry documents the realities of cancer care, clinical trials, and loss
Her collection, “To See Yourself As You Vanish,” will be published three years after her death

In phase III trial, epcoritamab regimen improves PFS in R/R follicular lymphoma

Will MCD tests revolutionize cancer screening? NCI begins enrollment in Vanguard “feasibility” trial to start finding out

Renew today!

Subscriber content

Never miss an issue!

Login

Repurposed drug has promising efficacy in shrinking NSCLC tumors

YOU MAY BE INTERESTED IN

FDA will speed up public release of Complete Response Letters

UC San Diego awarded $80M to expand clinical trials and train future researchers

IO Biotech’s vaccine misses on mPFS in phase III advanced melanoma trial

Andrea Werblin Reid’s unflinching poetry documents the realities of cancer care, clinical trials, and lossHer collection, “To See Yourself As You Vanish,” will be published three years after her death

In phase III trial, epcoritamab regimen improves PFS in R/R follicular lymphoma

Will MCD tests revolutionize cancer screening? NCI begins enrollment in Vanguard “feasibility” trial to start finding out

Never miss an issue!

Login

Andrea Werblin Reid’s unflinching poetry documents the realities of cancer care, clinical trials, and loss
Her collection, “To See Yourself As You Vanish,” will be published three years after her death